PRKN and hepatocellular carcinoma: Inhibition of CDK9 can block the initiation of PINK1-PRKN-mediated mitochondrial phagocytosis by regulating the SIRT1-FOXO3-BNIP3 axis and enhance the therapeutic effect of mitochondrial dysfunction in hepatocellular carcinoma [51].